Payment overview · 2025
General Payments
$497.50
26 reported records · 8 companies
Healthcare provider profile · identity verified
Anooja Philip, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · APOPKA, FL · NPI 1124423918
Verified facts
What the public records show
CMS Open Payments records show Anooja Philip, ARNP received $497.50 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $187.22 | 37.6% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $101.47 | 20.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.95 | 10.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.04 | 10.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.98 | 8.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.11 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.71 | 3.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.02 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $497.50 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.67 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $101.47 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $75.91 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.95 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 292 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 113 |
| Lisinopril | Lisinopril | 268 | 94 |
| Gabapentin | Gabapentin | 210 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 71 |
| Losartan Potassium | Losartan Potassium | 189 | 72 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 187 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 59 |
| Omeprazole | Omeprazole | 158 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 157 | 65 |
| Baclofen | Baclofen | 144 | 71 |
| Metformin Hcl | Metformin Hcl | 143 | 57 |
| Furosemide | Furosemide | 130 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 61 |
| Buspirone Hcl | Buspirone Hcl | 120 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 45 |
| Sertraline Hcl | Sertraline Hcl | 104 | 49 |
| Azithromycin | Azithromycin | 101 | 85 |
| Trazodone Hcl | Trazodone Hcl | 100 | 39 |
| Simvastatin | Simvastatin | 82 | 26 |
| Alendronate Sodium | Alendronate Sodium | 77 | 32 |
| Carvedilol | Carvedilol | 77 | 28 |
| Ozempic | Semaglutide | 66 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 65 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 16 |
| Azelastine Hcl | Azelastine Hcl | 58 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 19 |
| Jardiance | Empagliflozin | 58 | 23 |
| Metformin Hcl Er | Metformin Hcl | 58 | 25 |
| Prednisone | Prednisone | 55 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 26 |
| Meloxicam | Meloxicam | 48 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 21 |
| Allopurinol | Allopurinol | 43 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Linzess | Linaclotide | 40 | 17 |
| Famotidine | Famotidine | 37 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 16 |
| Naproxen | Naproxen | 36 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 12 |
| Cephalexin | Cephalexin | 34 | 29 |
| Mirtazapine | Mirtazapine | 34 | 17 |
| Glipizide | Glipizide | 33 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Potassium Chloride | Potassium Chloride | 29 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | 14 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Nystatin | Nystatin | 22 | 16 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $497.50 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, OTEZLA, REPATHA, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error